Regeneron Pharmaceuticals
REGN
$739.57
-0.34%
Regeneron Pharmaceuticals is a fully integrated biotechnology company that discovers, develops, and commercializes medicines across eye disease, cardiovascular disease, cancer, immunology, and inflammation, with a marketed portfolio led by Eylea/Eylea HD in ophthalmology, Dupixent in immunology, Libtayo in oncology, Praluent, Kevzara, and Lynozyfic in multiple myeloma. The company is one of the largest and most profitable independent biotechs globally, distinguished by its proprietary VelocImmune and VelociSuite antibody discovery platforms and long-standing co-development partnerships with Sanofi (Dupixent and others) and Bayer (Eylea), which provide both revenue sharing and pipeline leverage. The current investor narrative is dominated by two opposing forces: a sharp second-quarter 2026 earnings beat and accelerating top-line growth that has re-ignited the bull case, versus a May 2026 Phase 3 clinical trial failure for a key oncology combination that underscored pipeline concentration risk and triggered a steep single-day selloff. Investors are also debating the durability of Eylea HD's franchise against biosimilar and competitive pressure, the trajectory of Dupixent's expansion into new indications, and whether the company's growing cash pile will be deployed into business development or returned via buybacks, with the stock's recent pullback from August highs keeping valuation and pipeline execution front and center.…
REGN
Regeneron Pharmaceuticals
$739.57
Related headlines
Investment Opinion: Should I buy REGN Today?
Regeneron presents a compelling investment case with a consensus analyst rating of 'Buy' and an average target price of $853.19, implying 16.0% upside from the current price of $735.20. The company's Q2 2026 earnings beat, with revenue growth of 16.7% year-over-year and EPS of $12.59, demonstrates strong operational execution. However, the recent Phase 3 oncology trial failure and competitive pressures on Eylea introduce significant uncertainty, warranting a 'Hold' rating for risk-averse investors while offering a 'Buy' opportunity for those with higher risk tolerance and a long-term horizon.
The supporting evidence for a positive rating includes Regeneron's exceptional profitability, with a net margin of 31.4% and gross margin of 85.4%, and a robust balance sheet with a debt-to-equity ratio of just 0.087. The forward P/E of 12.1x is attractive relative to the trailing P/E of 17.9x, suggesting expected earnings growth. Additionally, the company generates substantial free cash flow of $3.52 billion, providing flexibility for reinvestment or shareholder returns. The price-to-sales ratio of 5.63 and EV/EBITDA of 13.81 are reasonable for a biotech with a strong pipeline, though the PEG ratio of 3.38 indicates the stock is not cheap relative to growth.
The biggest risks that could invalidate the thesis include further pipeline failures, accelerated Eylea biosimilar erosion, and a high PEG ratio suggesting overvaluation. The rating would upgrade to 'Buy' if the stock pulls back to the $650-$700 range or if pipeline successes materialize, and downgrade to 'Sell' if revenue growth decelerates below 10% or if Eylea sales decline more than expected. Currently, the stock appears fairly valued, trading at a premium to some peers but justified by its profitability and pipeline potential. Investors should monitor pipeline news and Eylea HD adoption closely.
Sign up to view all
REGN 12-Month Price Forecast
Regeneron presents a balanced risk-reward profile, with strong fundamentals and growth prospects offset by pipeline concentration and competitive threats. The stock's recent pullback and attractive forward valuation provide a margin of safety, but the PEG ratio of 3.38 suggests it is not deeply undervalued. Analyst sentiment remains positive, with a Buy rating and 16% upside to the average target, but the recent trial failure highlights execution risk. I would upgrade to bullish if pipeline successes materialize and Eylea HD adoption accelerates, or downgrade to bearish if revenue growth decelerates below 10% or if Eylea erosion worsens. The 12-month outlook is cautiously optimistic, with a base case target of $800-$900.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Regeneron Pharmaceuticals's 12-month outlook, with a consensus price target around $856.23 and implied upside of +15.8% versus the current price.
Average Target
$856.23
0 analysts
Implied Upside
+15.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$730 - $1030
Analyst target range
Bulls vs Bears: REGN Investment Factors
The bull case for Regeneron rests on its robust Q2 2026 earnings beat, exceptional profitability, fortress balance sheet, and attractive forward valuation, supported by a consensus Buy rating and 16% upside to analyst targets. However, the bear case is equally compelling, highlighted by a recent Phase 3 oncology trial failure, competitive threats to the Eylea franchise, and a PEG ratio of 3.38 that suggests the stock is not cheap. The most critical tension is whether Regeneron can successfully diversify its pipeline and offset potential Eylea declines with new growth drivers like Dupixent and Eylea HD. Currently, the bear evidence appears slightly stronger given the recent trial failure and negative momentum, but the strong fundamentals and analyst optimism provide a counterbalance. Resolution of pipeline execution and clarity on Eylea's trajectory will be pivotal in determining the stock's direction.
Bullish
- Q2 2026 Earnings Beat with Accelerating Growth: Regeneron reported Q2 2026 revenue of $4.29 billion, up 16.7% year-over-year, and EPS of $12.59, a sharp acceleration from Q1 2026's $6.99 EPS. This beat re-ignited the bull case and demonstrates the company's ability to grow its top line despite competitive pressures.
- Exceptional Profitability and Cash Generation: The company boasts a net margin of 31.4%, gross margin of 85.4%, and operating margin of 24.9%, with trailing free cash flow of $3.52 billion. These metrics underscore Regeneron's efficient cost structure and strong cash-generating ability.
- Fortress Balance Sheet with Minimal Debt: With a debt-to-equity ratio of just 0.087 and a current ratio of 4.13, Regeneron carries negligible leverage and ample liquidity. This provides significant financial flexibility for pipeline investment, business development, or shareholder returns.
- Attractive Forward Valuation and Analyst Upside: The stock trades at a forward P/E of only 12.1x, well below the trailing P/E of 17.9x, suggesting expected earnings growth. Analysts have a consensus 'Buy' rating with an average target price of $853.19, implying 16.0% upside from the current price of $735.20.
Bearish
- Recent Phase 3 Oncology Trial Failure: In May 2026, a key Phase 3 clinical trial for an oncology combination failed, triggering a steep single-day selloff and highlighting pipeline concentration risk. This setback raises concerns about the company's ability to diversify beyond its existing franchises.
- Eylea Franchise Faces Biosimilar and Competitive Pressure: Eylea, a core revenue driver, faces looming biosimilar competition and potential market share erosion. The transition to Eylea HD may not fully offset declines in the base franchise, creating a revenue headwind.
- High Valuation Relative to Growth Prospects: The PEG ratio of 3.38 suggests the stock may be overvalued relative to its expected earnings growth. Additionally, the price-to-sales ratio of 5.63 and EV/EBITDA of 13.81 are not inexpensive for a biotech with pipeline setbacks.
- Recent Stock Weakness and Negative Momentum: The stock has declined 13.7% over the past month and 5.3% year-to-date, significantly underperforming the S&P 500's 12.9% YTD gain. This negative relative strength (-18.2% YTD) indicates waning investor confidence.
REGN Technical Analysis
Beta
0.15
0.15x market volatility
Max Drawdown
-26.1%
Largest decline past year
52-Week Range
$541-$859
Price range past year
Annual Return
+31.2%
Cumulative gain past year
| Period | REGN Return | S&P 500 |
|---|---|---|
| 1m | -8.7% | +1.0% |
| 3m | +11.3% | +2.5% |
| 6m | -1.2% | +13.9% |
| 1y | +31.2% | +15.0% |
| ytd | -4.7% | +13.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
REGN Fundamental Analysis
Quarterly Revenue
$4.3B
2026-06
Revenue YoY Growth
+16.7%
YoY Comparison
Gross Margin
86.6%
Latest Quarter
Free Cash Flow
$3.5B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is REGN Overvalued?
PE
17.9x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 8x~28x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks for Regeneron are relatively contained due to its strong balance sheet, but the company's heavy reliance on a few key products poses a concentration risk. Eylea and Dupixent together account for a substantial portion of revenue, and any competitive or regulatory setback could materially impact results. The recent Phase 3 oncology trial failure exemplifies the inherent volatility of drug development, and with R&D spending at $1.63 billion in Q2 2026, continued pipeline disappointments could pressure margins. Additionally, while the debt-to-equity ratio is low at 0.087, the company's growth prospects are tied to successful commercialization of new indications, and any slowdown could lead to earnings misses.
Market and competitive risks include the threat of biosimilar competition to Eylea, which could erode pricing and market share. The ophthalmology market is becoming increasingly crowded, and Regeneron's ability to transition patients to Eylea HD will be critical. Furthermore, the stock's low beta of 0.193 suggests it is less sensitive to market swings, but sector rotation away from healthcare could still weigh on performance. Regulatory headwinds, such as potential drug pricing reforms, and macroeconomic factors like interest rate changes could also affect valuation, especially given the stock's premium multiples.
The worst-case scenario for Regeneron would involve a combination of further pipeline failures, accelerated Eylea erosion, and a broader biotech selloff. In such a scenario, the stock could retest its 52-week low of $541.00, representing a decline of approximately 26.4% from the current price of $735.20. This is in line with the stock's max drawdown of -26.05% over the past year. If analyst bear-case targets are met, the downside could be even more severe, with the low target at $730.00 already near the current price, but a more pessimistic view could see the stock fall below $600 if growth stalls.
FAQ
The key risks for Regeneron include pipeline concentration, competitive threats, and valuation risk. The recent Phase 3 oncology trial failure highlights the company's dependence on a few key programs, and further setbacks could significantly impact growth prospects. Eylea faces biosimilar competition, and the transition to Eylea HD may not fully offset declines. Additionally, the stock's PEG ratio of 3.38 suggests it is priced for growth, and any slowdown could lead to a de-rating. Macroeconomic factors, such as drug pricing reforms, and the company's low beta of 0.193 do not fully insulate it from sector-specific headwinds. These risks are ranked from high (pipeline) to moderate (valuation).
Our 12-month forecast for Regeneron includes a base case (50% probability) with a target range of $800-$900, assuming steady revenue growth and no major pipeline surprises. The bull case (30% probability) targets $900-$1030, driven by pipeline successes and accelerated Eylea HD adoption. The bear case (20% probability) sees a decline to $541-$650, triggered by further pipeline failures or faster Eylea erosion. The most likely scenario is the base case, with the key assumption being that Regeneron maintains mid-teens revenue growth and successfully navigates competitive pressures. Analyst consensus aligns with this view, with an average target of $853.19.
Regeneron's valuation appears fairly valued to slightly overvalued on some metrics. The forward P/E of 12.1x is low relative to the trailing P/E of 17.9x, suggesting expected earnings growth, but the PEG ratio of 3.38 indicates the stock is not cheap relative to its growth rate. The price-to-sales ratio of 5.63 and EV/EBITDA of 13.81 are in line with large-cap biotech peers. Compared to its own history, the stock is trading at a discount to its 52-week high of $859.34 but at a premium to its low of $541.00. The market appears to be pricing in mid-teens earnings growth, and any disappointment could lead to multiple compression.
Regeneron offers a compelling risk/reward proposition for long-term investors, with a consensus Buy rating and an average analyst target of $853.19, implying 16% upside from the current price of $735.20. The company's Q2 2026 earnings beat, with 16.7% revenue growth and EPS of $12.59, demonstrates strong execution, while its forward P/E of 12.1x is attractive. However, the recent Phase 3 oncology trial failure and competitive threats to Eylea introduce significant uncertainty. For investors with a higher risk tolerance and a multi-year horizon, REGN could be a good buy, especially on dips. Those seeking lower volatility may prefer to wait for clearer pipeline visibility.
Regeneron is more suitable for long-term investment due to its strong fundamentals, innovative pipeline, and history of value creation, despite near-term volatility. The stock's beta of 0.193 indicates low market correlation, but it is still subject to sector-specific risks and pipeline news. With a dividend yield of just 0.46%, it is not an income play, but the potential for capital appreciation is significant. Short-term trading is risky given the binary nature of clinical trial outcomes and earnings reports. A minimum holding period of 3-5 years is recommended to allow for pipeline maturation and market cycle navigation. Investors should monitor quarterly results and pipeline updates closely.